Skip to main content

Charting the Tumor Immune Microenvironment: Advances in Spatial Profiling and Novel Therapeutic Avenues

Edited by:

Anna Dimberg, PhD, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Sweden
Paola Nisticò, MD, IRCCS-Regina Elena National Cancer Institute, Italy 
Nicla Porciello, PhD, IRCCS-Regina Elena National Cancer Institute, Italy 
Alice Castelli, PhD, Managing Editor, Journal of Experimental & Clinical Cancer Research, IRCCS-Regina Elena National Cancer Institute, Italy

Submission Status: Open   |   Submission Deadline: 30 June 2025 


Journal of Experimental & Clinical Cancer Research is calling for submissions to our Collection on “Charting the Tumor Immune Microenvironment: Advances in Spatial Profiling and Novel Therapeutic Avenues”. In this Collection, we aim to offer a comprehensive overview of the current landscape of the Tumor Immune Microenvironment (TIME) properties, considering cellular and non-cellular components, emphasizing innovative technologic tools to clinically translate recent research breakthroughs (1).

About the Collection

Journal of Experimental & Clinical Cancer Research is calling for submissions to our Collection on “Charting the Tumor Immune Microenvironment: Advances in Spatial Profiling and Novel Therapeutic Avenues”. In this Collection, we aim to offer a comprehensive overview of the current landscape of the Tumor Immune Microenvironment (TIME) properties, considering cellular and non-cellular components, emphasizing innovative technologic tools to clinically translate recent research breakthroughs (1). Cancer-intrinsic factors such as genetic alterations, a broad range of cellular TIME components including cancer-associated fibroblasts, endothelial cells, and immune cells, along with extracellular matrix and soluble factors like cytokines, interact with each other to either suppress or favor anti-tumor immunity (2-7). Unveiling this reciprocal dialogue, the dynamics, and the spatial positioning of TIME components is fundamental to improving patient clinical outcomes and identifying the molecular mechanisms underlying TIME-mediated immunomodulation and utilize TIME landscape for clinical applications. The integration of high-resolution technologies and computational developments is significantly accelerating the addressing of these fundamental issues. This may open up novel translational and clinical opportunities for the development of more effective therapeutic combinations with the potential to significantly improve and broaden the response to therapy in solid tumors. 

References:

1. Toninelli M, Rossetti G, Pagani M. Charting the tumor microenvironment with spatial profiling technologies. Trends Cancer. 2023 Dec;9(12):1085-1096
2. Di Modugno F, Di Carlo A, Spada S, Palermo B, D'Ambrosio L, D'Andrea D, Morello G, Belmonte B, Sperduti I, Balzano V, Gallo E, Melchionna R, Panetta M, Campo G, De Nicola F, Goeman F, Antoniani B, Carpano S, Frigè G, Warren S, Gallina F, Lambrechts D, Xiong J, Vincent BG, Wheeler N, Bortone DS, Cappuzzo F, Facciolo F, Tripodo C, Visca P, Nisticò P. Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer. EBioMedicine. 2024 Mar;101:105003
3. Ramachandran M, Vaccaro A, van de Walle T, Georganaki M, Lugano R, Vemuri K, Kourougkiaouri D, Vazaios K, Hedlund M, Tsaridou G, Uhrbom L, Pietilä I, Martikainen M, van Hooren L, Olsson Bontell T, Jakola AS, Yu D, Westermark B, Essand M, Dimberg A. Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma. Cancer Cell. 2023 Jun 12;41(6):1134-1151
4. Enfield KSS, Colliver E, Lee C, Magness A, Moore DA, Sivakumar M, Grigoriadis K, Pich O, Karasaki T, Hobson PS, Levi D, Veeriah S, Puttick C, Nye EL, Green M, Dijkstra KK, Shimato M, Akarca AU, Marafioti T, Salgado R, Hackshaw A; TRACERx consortium; Jamal-Hanjani M, van Maldegem F, McGranahan N, Glass B, Pulaski H, Walk E, Reading JL, Quezada SA, Hiley CT, Downward J, Sahai E, Swanton C, Angelova M. Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer. Cancer Discov. 2024 Jun 3;14(6):1018-1047
5. Meylan M, Petitprez F, Becht E, Bougoüin A, Pupier G, Calvez A, Giglioli I, Verkarre V, Lacroix G, Verneau J, Sun CM, Laurent-Puig P, Vano YA, Elaïdi R, Méjean A, Sanchez-Salas R, Barret E, Cathelineau X, Oudard S, Reynaud CA, de Reyniès A, Sautès-Fridman C, Fridman WH. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity. 2022 Mar 8;55(3):527-541
6. Ruffin AT, Li H, Vujanovic L, Zandberg DP, Ferris RL, Bruno TC. Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment. Nat Rev Cancer. 2023 Mar;23(3):173-188
7. Croizer H, Mhaidly R, Kieffer Y, Gentric G, Djerroudi L, Leclere R, Pelon F, Robley C, Bohec M, Meng A, Meseure D, Romano E, Baulande S, Peltier A, Vincent-Salomon A, Mechta-Grigoriou F. Deciphering the spatial landscape and plasticity of immunosuppressive fibroblasts in breast cancer. Nat Commun. 2024 Apr 1;15(1):2806

Keywords: Tumor Immune Microenvironment, Immune cells, Tertiary Lymphoid Structures, Cancer Associated Fibroblasts, Endothelial Cells, Spatial Transcriptomics, Cytokines, Solid Tumors 

Image credit: © Nicla Porciello

  1. Lung cancer is a serious threat to human life and health, but effective screening and treatment methods are lacking. Circular RNAs (circRNAs) have important biological functions and are closely related to tumo...

    Authors: Haotian Xu, Qingyun Zhao, Dunyu Cai, Xingcai Chen, Xiaodong Zhou, Yihong Gao, Jiaxi Wu, Shengyi Yuan, Deqing Li, Ruirui Zhang, Wenyi Peng, Gang Li and Aruo Nan
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:110
  2. Addressing the challenges of identifying suitable targets and effective delivery strategies is critical in pursuing therapeutic solutions for glioblastoma (GBM). This study focuses on the therapeutic potential...

    Authors: Po-Fu Yueh, I-Tsang Chiang, Yueh-Shan Weng, Yu-Chang Liu, Raymond C. B. Wong, Cheng-Yu Chen, Justin Bo-Kai Hsu, Long-Bin Jeng, Woei-Cherng Shyu and Fei-Ting Hsu
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:107
  3. Oncolytic adenoviruses are among the most widely utilized oncolytic viruses due to their notable anti-tumor and gene expression capabilities, and modification of ADVs to create armed adenoviruses remains a pop...

    Authors: Shuo Wang, Lingkai Kong, Linpei Wang, Yan Zhuang, Ciliang Guo, Yuxin Zhang, Huawei Cui, Xiaosong Gu, Junhua Wu and Chunping Jiang
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:97
  4. The identification of molecular features characterizing metastatic disease is a critical area of oncology research, as metastatic foci often exhibit distinct biological behaviors compared to primary tumors. Wh...

    Authors: Giorgio Bertolazzi, Valeria Cancila, Davide Vacca, Beatrice Belmonte, Daniele Lecis, Parsa Sirati Moghaddam, Arianna Di Napoli, Mario Paolo Colombo, Giancarlo Pruneri, Giannino Del Sal, Giorgio Scita, Matteo Fassan, Andrea Vecchione, Silvio Bicciato and Claudio Tripodo
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:89
  5. The ubiquitously expressed transmembrane protein, Herpesvirus Entry Mediator (HVEM), functions as a molecular switch, capable of both activating and inhibiting the immune response depending on its interacting ...

    Authors: Yuanshan Yao, Bin Li, Jing Wang, Chunji Chen, Wen Gao and Chunguang Li
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:62
  6. Co-targeting of immune checkpoint inhibitors (ICI) CTLA-4 and PD-1 has recently become the new first-line standard of care therapy of pleural mesothelioma (PM) patients, with a significant improvement of overa...

    Authors: Maria Fortunata Lofiego, Rossella Tufano, Emma Bello, Laura Solmonese, Francesco Marzani, Francesca Piazzini, Fabrizio Celesti, Francesca Pia Caruso, Teresa Maria Rosaria Noviello, Roberta Mortarini, Andrea Anichini, Michele Ceccarelli, Luana Calabrò, Michele Maio, Sandra Coral, Anna Maria Di Giacomo…
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:58
  7. Glioma, particularly glioblastoma (GBM), is a highly aggressive tumor with limited responsiveness to immunotherapy. PANoptosis, a form of programmed cell death merging pyroptosis, apoptosis, and necroptosis, p...

    Authors: Yonghua Cai, Heng Xiao, Shuaishuai Xue, Peng Li, Zhengming Zhan, Jie Lin, Zibin Song, Jun Liu, Wei Xu, Qixiong Zhou, Songtao Qi, Xi’an Zhang and Ziyi Luo
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:35
  8. The benefit of universal CAR-T cells over autologous CAR-T cell therapy is that they are a treatment that is ready to use. However, the prevention of graft-versus-host disease (GVHD) and host-versus-graft reac...

    Authors: Shuxian Zhu, Shiyu Zuo, Chuo Li, Xingjie You, Erlie Jiang, Xiaoming Feng and Yuechen Luo
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:25
  9. Head and neck squamous cell carcinoma (HNSCC) is a very aggressive disease characterized by a heterogeneous tumor immune microenvironment (TIME). Tumor-associated macrophages (TAMs) constitute the major innate...

    Authors: Chun Liu, Kun Wu, Chuwen Li, Zhen Zhang, Peisong Zhai, Haiyan Guo and Jianjun Zhang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:332
  10. Ferroptosis is a type of regulated cell death characterized by its non-apoptotic, iron-dependent and oxidative nature. Since its discovery in 2012, extensive research has demonstrated its pivotal roles in tumo...

    Authors: Kaisa Cui, Kang Wang and Zhaohui Huang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:315
  11. Glioblastoma (GBM), an incurable primary brain tumor, typically requires surgical intervention followed by chemoradiation; however, recurrences remain fatal. Our previous work demonstrated that a nanomedicine ...

    Authors: Chiara Bastiancich, Emmanuel Snacel-Fazy, Samantha Fernandez, Stéphane Robert, Roberta Stacchini, Léa Plantureux, Sébastien Boissonneau, Benoit Testud, Benjamin Guillet, Franck Debarbieux, Hervé Luche, Dominique Figarella-Branger, Marie-Anne Estève, Emeline Tabouret and Aurélie Tchoghandjian
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:311
  12. Melanoma progression is based on a close interaction between cancer cells and immune cells in the tumor microenvironment (TME). Thus, a better understanding of the mechanisms controlling TME dynamics and compo...

    Authors: Alessandro Giammona, Chiara De Vellis, Enrica Crivaro, Luisa Maresca, Roberta Amoriello, Federica Ricci, Giulia Anichini, Silvia Pietrobono, David R. Pease, Martin E. Fernandez-Zapico, Clara Ballerini and Barbara Stecca
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:214
  13. Pancreatic cancer (PC) is a clinically challenging tumor to combat due to its advanced stage at diagnosis as well as its resistance to currently available therapies. The absence of early symptoms and known det...

    Authors: Carla Mottini, Francesca Romana Auciello, Isabella Manni, Christian Pilarsky, Damiano Caputo, Giulio Caracciolo, Alessandro Rossetta, Elena Di Gennaro, Alfredo Budillon, Giovanni Blandino, Maria Serena Roca and Giulia Piaggio
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:198
  14. Pyroptosis is a cell death process characterized by cell swelling until membrane rupture and release of intracellular contents. As an effective tumor treatment strategy, inducing tumor cell pyroptosis has rece...

    Authors: Mengyuan Hu, Fengying Deng, Xinlei Song, Hongkun Zhao and Fei Yan
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:190

Submission Guidelines

Back to top

This Collection welcomes submission of Research articles and Reviews. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. 

Articles for this Collection should be submitted via our submission system, SNAPP. Please select the appropriate Collection title “Charting the Tumor Immune Microenvironment: Advances in Spatial Profiling and Novel Therapeutic Avenues" from the dropdown menu. Articles will undergo the journal’s standard peer-review process and are subject to all the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer-review process. The peer-review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.